A MULTINATION PHASE II TRIAL OF BEVACIZUMAB WITH LOW-DOSE INTERFERON-ALPHA2A AS FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA: BEVLIN СтатьяMelichar B., Bracarda S., Matveev V., Flekseev B., Ivanov S., Zyryanov A., Janciauskiene R., Fernebro E., Mulders P., Osborne S., Jethwa S., Mickisch G., Gore M., R.J.A. Van, Staehler M., Magne N., Bellmunt J.Annals of Oncology. Том V24. 2013.
OUTCOME OF TREATMENT DISCONTINUATION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA AND NO EVIDENCE OF DISEASE FOLLOWING TARGETED THERAPY WITH OR WITHOUT METASTASECTOMY СтатьяJohannsen M., Miller K., Weikert S., Staehler M., Ohlmann C.H., Flörcken A., Schmittel A., Otto T., Bex A., Hein P., Grünwald V.Annals of Oncology. Том 22. 2011. С. 657-663
